Life Sciences

Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.



Sign up for a 7-day FREE trial today!



Latest News in Life Sciences

  • October 30, 2026

    Judge Won't Free Pierce Atwood Of Investor's Malpractice Suit

    Pierce Atwood LLP failed to win dismissal of a lawsuit from a Ukrainian oligarch who says the firm's advice led to a $1.85 million judgment against him in investor litigation over the liquidation of now-insolvent genetic testing company Pathway Genomics Corp.

  • October 29, 2026

    Judge 'Put Off' By Atty Fee Bid In $59.5M Menstrual App Deal

    A California federal judge said Thursday that he'll give final approval to a $59.5 million settlement resolving class claims over a menstrual tracking app sharing sensitive health data with Google, but he cut the $19 million attorney fee request by 5%, saying counsel is "taking money out of consumers' pockets."

  • October 29, 2026

    Colo. Justices Won't Review Hospital's Injunction Compliance

    The Colorado Supreme Court declined Thursday to take up transgender youth patients' challenge to a Denver judge's ruling that discharged their contempt citation against Children's Hospital Colorado for not resuming providing medical gender-affirming care to transgender adolescents.

  • October 29, 2026

    Fertility Cos. Accused Of Moving Eggs Without Consent

    A national fertility clinic network has been hit with a suit in Los Angeles Superior Court alleging it jeopardized a 50-year-old woman's ability to have a biological child by transporting her frozen eggs across state lines to an automated facility without her permission.

  • October 29, 2026

    Camp Lejeune Plaintiffs Blast 'Absurd' Lone Pine Motion

    Plaintiffs in massive multidistrict litigation over toxic water at the Camp Lejeune military base are urging a North Carolina federal court to reject the federal government's bid for a Lone Pine motion requiring claimants to submit proof of their claims, saying it would delay the litigation by years, if not decades, and cause the plaintiffs' costs to skyrocket.

See more Life Sciences news

Life Sciences

Areas of Coverage

  • AGENCIES
  • U.S. Consumer Product Safety Commission
  • U.S. Food and Drug Administration
  • U.S. Patent and Trademark Office
  • U.S. International Trade Commission
  • POLICY & REGULATION
  • Affordable Care Act
  • Federal Food, Drug, and Cosmetic Act
  • Antitrust and consumer protection controls
  • Drug and medical device lobbying
  • State and international life sciences legislation and regulation
  • ENFORCEMENT
  • Drug and medical device recalls
  • Drug safety actions
  • Pay-for-delay investigations
  • Merger reviews
  • LITIGATION
  • Patent disputes, including
  • Abbreviated New Drug Application litigation
  • Section 301 cases
  • Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
  • Consumer litigation and class actions
  • Fraud and compliance suits
  • Antitrust disputes
  • Labor and employment suits
  • Shareholder and corporate governance disputes
  • Bankruptcy proceedings
  • TRANSACTIONS
  • Mergers, acquisitions, and joint ventures
  • Share buybacks and stock splits
  • Private equity deals
  • Patent-licensing agreements
  • PROFILES
  • Personnel moves
  • Profiles of life sciences practice groups

Readership

  • Life sciences lawyers at top law firms
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Executives and attorneys in the drug, biotechnology, and medical device industries
  • Information experts at law firms, agencies, and companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals